MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ALNY made $3,713,937K in revenue. $328,168K in net income. Net profit margin of 8.84%.

Income Overview

Revenue
$3,713,937K
Net Income
$328,168K
Net Profit Margin
8.84%
EPS
$2.33
Unit: Thousand (K) dollars
Revenue Breakdown
    • Amvuttra
    • Roche
    • GIVLAARI
    • Others

Income Statement
2025-12-31
Total revenues
3,713,937
Cost of goods sold
677,166
Cost of collaborations and royalties
4,705
Research and development
1,319,775
Selling, general and administrative
1,210,713
Total operating costs and expenses
3,212,359
Income (loss) from operations
501,578
Interest expense
252,627
Interest income
111,470
Loss related to convertible debt
42,473
Other income (expense), net
5,204
Total other expense, net
-178,426
Income (loss) before income taxes
323,152
(provision for) benefit from income taxes
9,405
Net income (loss)
313,747
Unrealized gains (losses) on marketable securities
1,816
Foreign currency translation gains (losses)
11,624
Defined benefit pension plans, net of tax
-981
Net other comprehensive loss
14,421
Comprehensive income (loss)
328,168
Basic EPS
2.39
Diluted EPS
2.33
Basic Average Shares
131,004,000
Diluted Average Shares
134,684,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
US$1,731,222K Europe$405,899K Non USOr Europe$176,715K Europe$79,429K US$62,126K Non USOr Europe$31,234K US$205,715K Europe$77,715K Non USOr Europe$25,057K Europe$88,049K US$68,467K Non USOr Europe$34,921K Amvuttra$2,313,836K ONPATTRO$172,789K GIVLAARI$308,487K OXLUMO$191,437K TTR$2,486,625K Rare$499,924K Roche$394,881K RegeneronPharmaceuticals Incorporation$113,957K Other Collaborations$44,528K Product$2,986,549K Collaborations$553,366K Royalty$174,022K Total revenues$3,713,937K Income (loss) fromoperations$501,578K Total operating costsand expenses$3,212,359K Income (loss) beforeincome taxes$323,152K Foreign currencytranslation gains (losses)$11,624K Unrealized gains (losses)on marketable...$1,816K Defined benefit pensionplans, net of tax-$981K Total other expense,net-$178,426K Interest income$111,470K Research and development$1,319,775K Selling, general andadministrative$1,210,713K Cost of goods sold$677,166K Cost ofcollaborations and royalties$4,705K Other income(expense), net$5,204K Net income (loss)$313,747K Net othercomprehensive loss$14,421K (provision for) benefitfrom income taxes$9,405K Interest expense$252,627K Loss related toconvertible debt$42,473K Comprehensive income (loss)$328,168K

ALNYLAM PHARMACEUTICALS, INC. (ALNY)

ALNYLAM PHARMACEUTICALS, INC. (ALNY)